Mar 5, 2025 · C5a promotes cSCC cell invasion, and the expression of C5aR1 is linked to metastatic risk and poor prognosis in patients with cSCC. These findings suggest that C5aR1 could serve as a potential metastatic risk marker, a novel prognostic biomarker, and promising therapeutic target for cSCC.

These findings suggest a role of C5a in cSCC cell invasion and identify C5aR1 as a novel biomarker for metastasis risk and poor prognosis in patients with cSCC. The results also suggest that C5aR1 could be a novel therapeutic target for treatment of …

C5a antibody (vilobelimab/IFX-1) is currently tested alone or in combination with pembrolizumab in locally advanced or metastatic CSCC (NCT04812535). Finally, since the gut microbiome has been implicated in resistance to ICIs, combined therapies with bacteria plus immunotherapy have been developed.

These findings suggest a role of C5a in cSCC cell invasion, and they identify C5aR1 as a novel biomarker for metastasis risk and poor prognosis in patients with cSCC. The results also suggest that C5aR1 could be a novel therapeutic target for the treatment of locally advanced and metastatic cSCC.

Oct 20, 2024 · A recent study suggests that C3b could impact tumorigenesis during chronic skin inflammation, in cutaneous squamous cell carcinoma (cSCC) model, but independently of C3aR or the terminal pathway (C5a/C5aR1/C5aR2 and MAC generation), likely by influencing tumor associated macrophages .

These results reveal the role of C5aR1 in cSCC progression and identify C5aR1 as a novel biomarker for metastasis risk and poor prognosis of patients with cSCC. The results also suggest C5aR1 as a novel therapeutic target for treatment of locally advanced and metastatic cSCC.

Expression of the receptors for C5a (C5aR) is increased in many epithelial tumours, including cSCC. C5a is expressed at high levels in the tumor environment and may directly promote tumor growth and, through several mechanisms, metastasis.

Oct 8, 2018 · Anaphylatoxins and the downstream pathways they regulate are emerging tractable targets for anticancer immunotherapy. Results presented herein identify uPA-expressing macrophages as critical regulators of C3-independent C5a generation in squamous cell carcinomas (SCCs) that sustain immunosuppressive tumor immune microenvironments (TiMEs).

Mar 6, 2025 · C5a promotes cSCC cell invasion, and the expression of C5aR1 is linked to metastatic risk and poor prognosis in patients with cSCC. These findings suggest that C5aR1 could serve as a potential metastatic risk marker, a novel prognostic biomarker, and promising therapeutic target for cSCC.

Jan 6, 2021 · Complement factor C5a was originally identified as a powerful promoter of inflammation through activation of the C5a receptor 1 (C5ar1). Recent evidence suggests involvement of C5a not only in pro- but also in anti-inflammatory signaling.